In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

B. Braun Melsungen AG

https://www.bbraun.com/en.html

Latest From B. Braun Melsungen AG

Better Late Than Never: German Medtechs Make The Case For Practical MDR Improvements

A regulatory system that cannot function as intended, even with an extra year for preparation, will become mandatory in the EU next week. German medtechs suggest a route forward.

Regulation EU

Top 100 Review: The Calm Before The Storm – But Some Medtechs Already Reflect The Ravages Of COVID-19

2019 saw fewer revenues-boosting major acquisitions by top-tier medtechs. Companies that reported after the calendar year-end were the first to see the consequences of the pandemic on their annual figures.

Commercial Sales & Earnings

Not Too Late? German Industry Presses For EU MRA With Post-Brexit UK

BVMed says the EU and the UK should set up a system of mutual recognition of medical device regulation to kick in when the UK’s EU exit transition period ends on 31 December. 

EU Regulation

Market Brief: Global Orthobiologics Market Will Reach $2.3Bn By 2023 With Highest Growth In Cartilage Replacement

The global market for orthobiologics for musculoskeletal soft tissue replacement and regeneration is expected to reach $2.3bn by 2023, according to a new report by Informa's Meddevicetracker. This highly competitive market, which is led by Arthrex and other large and smaller players, continues to grow amid the rising prevalence of musculoskeletal soft tissue injuries and osteoarthritis. High prices of implants, the limited availability of donated tissue and limited reimbursement for synthetic scaffolds are limiting growth in this market.

Orthopedics Surgical Procedures
See All

Company Information

  • Industry
  • Distributors
  • Medical Devices
  • Services
    • Group Purchasing
    • Home Infusion
  • Medical Devices
    • Consumables, Central Supplies
    • Implantable Devices
    • Surgical Equipment & Devices
  • Other Names / Subsidiaries
    • Aesculap AG
    • Aesculap Inc.
    • Aesculap Implant Systems
    • B. Braun Medical Inc.
    • B. Braun Medical SAS
    • B. Braun Miethke GmbH & Co. KG
    • Central Admixture Pharmacy Services, Inc.
    • Dextera Surgical, Inc.
    • Lauer Membran Wassertechnik GmbH
    • McGaw, Inc.
UsernamePublicRestriction

Register